An interesting company to diligence is ACRS (Aclaris) - they have 2 Big Mover readouts coming this month for 2 different assets, and their market cap is less than $200M, yet 7 hedge funds hold them. It's very rare for this many hedge funds to hold a company with that market cap. However, in 2021 their market cap was 10X current, and we find that biopharma-focused hedge funds are not in a rush to pull out of holdings where they have lost big. We have not traced the hedge fund

An interesting company to diligence is ACRS (Aclaris) - they have 2 Big Mover readouts coming this month for 2 different assets, and their market cap is less than $200M, yet 7 hedge funds hold them. It's very rare for this many hedge funds to hold a company with that market cap. However, in 2021 their market cap was 10X current, and we find that biopharma-focused hedge funds are not in a rush to pull out of holdings where they have lost big. We have not traced the hedge fund

Summary:

Intro: Hedge Fund's led us to ACET

$XBI $69.18 | -2.85% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates # Pipeline Updates #CYCN +8.6%...

$XBI $69.18 | -2.85% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates # Pipeline Updates #CYCN +8.6%...

Summary: The American Society of Clinical Oncology (ASCO) Annual 2022 Meeting is taking place from June 3-7, 2022 See our prior post for...